Canine Monocytic Ehrlichi Infection in Dogs (Canine Monocytic Ehrlichiosis, CME)
- Synonyms: Monocytic ehrlichiosis, canine ehrlichiosis, tropical canine pancytopenia
- Occurrence: common
- Location of disease: General/Whole body
When to visit the vet?
Urgent see a veterinarian within 24 hours
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Canine monocytic ehrlichiosis is a tick-borne infectious disease in dogs caused by the bacterium Ehrlichia canis. It leads to an infection of white blood cells and can trigger a wide range of clinical symptoms.
Das Wichtigste auf einen Blick
Canine monocytic ehrlichiosis is a bacterial infection in dogs caused by bacteria of the genus Ehrlichia. These bacteria are mainly transmitted through the bite of the brown dog tick. The infection affects white blood cells and can weaken the dog’s immune system, making it more susceptible to further infections. The disease progresses in three phases: acute, subclinical, and chronic. In the acute phase, dogs often show non-specific symptoms such as Fever or loss of appetite. In the chronic phase, more severe symptoms such as anemia or organ damage can occur.
Diagnosis is based on clinical symptoms and special blood tests that can detect anemia or a low platelet count. Serological tests and PCR tests help confirm the infection. Treatment is usually with antibiotics, primarily doxycycline, for at least four weeks. In severe cases, supportive therapy may be necessary. Early diagnosis and treatment are crucial to control the disease and avoid complications.
For prevention, tick control is key. Regular use of tick repellents and checking the dog for ticks can reduce the risk of infection. Despite treatment, some dogs may remain carriers of the bacteria and are therefore prone to relapses. A vaccine against Ehrlichia canis does not currently exist, so tick control remains the most important prevention measure.
Ursachen
Ehrlichiosis is a bacterial infection caused by organisms of the genus Ehrlichia. These bacteria are obligate intracellular pathogens that preferentially live in monocytes and macrophages, which can lead to a systemic disease. The primary mode of transmission is the bite of infected ticks, especially the brown dog tick (Rhipicephalus sanguineus).
The infection begins when an infected tick feeds on a dog and transmits the bacteria into the dog’s bloodstream. The bacteria then infect white blood cells and multiply within these cells. This infection can suppress the immune system and make the dog susceptible to secondary infections.
The disease occurs in different phases: acute, subclinical, and chronic. In the acute phase, which can occur weeks to months after infection, the dog often shows non-specific symptoms. In the subclinical phase, the dog may show no symptoms, while the chronic phase causes more serious health problems such as anemia, a tendency to bleed, and organ damage.
Symptoms
- Cough
- Petechiae (pinpoint hemorrhages)
- Pale Mucous Membranes
- Susceptibility to Infection
- General condition impaired
- Retinal hemorrhages
- Hyphema (Intraocular Hemorrhage)
- Conjunctivitis
- Fluid accumulation in the abdominal cavity (ascites)
- Leg edema
- Vomiting
- Diarrhea
- Bauchschmerzen
- Neurological Symptoms Such as Seizures, Disorientation, Behavioral Disorders
Symptoms of canine monocytic ehrlichiosis can vary widely and depend on the phase of the disease. In the acute phase, dogs may show Fever, loss of appetite, Lethargy, and Weight loss. Enlarged lymph nodes and an enlarged spleen can also occur.
In the subclinical phase, the dog may show no obvious symptoms even though the infection persists in the body. This makes diagnosis difficult in this phase, as the dog may appear healthy.
In the chronic phase of the disease, more severe symptoms can occur. These include anemia, Bleeding that may appear as Nose bleeds (epistaxis) or bruising, as well as Joint pain and neurological symptoms. The chronic phase can also lead to failure of multiple organs, especially the kidneys.
Key symptoms: Fever spikes + Enlarged lymph nodes (lymphadenopathy) + Bleeding, Nose bleeds (epistaxis), pinpoint bleeding in the skin or mucous membranes (petechiae) ± Lameness after tick exposure.
Diagnose
The diagnosis of canine monocytic ehrlichiosis is based on a combination of clinical symptoms, the dog’s medical history, and specific diagnostic tests. Blood tests are crucial to detect abnormalities such as anemia, thrombocytopenia (low platelet count), and elevated liver enzyme levels.
Serological tests such as the indirect immunofluorescence assay (IFA) can be used to identify antibody against Ehrlichia canis in the dog’s blood. These tests indicate whether the dog has come into contact with the bacteria and responded to it.
Another diagnostic approach is the PCR test (polymerase chain reaction), which directly detects the presence of Ehrlichia DNA in the dog’s blood. This test is particularly useful in the early phase of infection, when antibody titers may not yet be detectable.
Therapie
Treatment of canine monocytic ehrlichiosis is usually with antibiotics. Doxycycline is the most commonly used antibiotic and is given for at least 4 weeks. Early treatment can quickly relieve symptoms and control the infection.
In severe cases, especially in the chronic phase, supportive therapy may be required. This can include giving fluids for hydration, blood transfusions for severe anemia, and treating secondary infections.
It is important to continue treatment consistently and have the dog monitored regularly by a veterinarian to ensure the infection is completely eliminated and no relapses occur.
Prognose und Nachsorge
The prognosis for dogs with canine monocytic ehrlichiosis depends on the phase of the disease and how quickly treatment begins. Dogs treated in the acute phase usually have a good prognosis and recover fully.
In the chronic phase, the prognosis is more guarded because irreversible organ damage can occur. Early diagnosis and treatment are crucial to minimize the risk of long-term complications.
Some dogs may remain carriers of the bacteria despite treatment and are prone to relapses, especially if the immune system is weakened.
Prävention
Prevention of canine monocytic ehrlichiosis focuses mainly on tick control. Regular use of tick repellents and checking the dog’s environment for tick infestation are important measures to reduce the risk of infection.
It is also advisable to check dogs regularly for ticks, especially after being in areas where ticks are common. Ticks should be removed as quickly as possible to prevent transmission of Ehrlichia bacteria.
Good general preventive care and regular veterinary check-ups can help monitor the dog’s health and respond early to possible infections. There is currently no vaccine against Ehrlichia canis, so tick control remains the most important prevention measure.
Ausblick auf aktuelle Forschung
Research into canine monocytic ehrlichiosis (Ehrlichia canis) is taking two paths: better detection and more targeted treatment. New blood tests combine antibody and PCR detection to find early infections faster and distinguish relapses. In addition, biomarkers in blood and urine are being evaluated to indicate whether the bone marrow is affected or the kidneys are involved. In therapy, researchers are investigating how long antibiotics are really needed and which regimens best prevent relapses. In parallel, combinations of an antibiotic plus anti-inflammatories are being tested to stabilize platelet counts more quickly. Another focus is protection against secondary damage such as kidney or eye inflammation: standardized follow-up plans with blood counts, coagulation values, and urine tests help here. Vector control remains central. Studies compare collars, spot-ons, and tablets in endemic areas and analyze whether seasonal strategies make sense. Co-infections transmitted by ticks (such as anaplasma or babesiosis) are also being sought more specifically because they can worsen the course. In the long term, vaccine approaches and immunomodulators are being researched to dampen excessive inflammatory responses without weakening defenses. The goal is an infection that is detected early, treated consistently, has a low risk of relapse, and provides reliable protection of the organs.